Study Suggests Online Search Data Can Help Early Detection Efforts
- A new study published in BMC Public Health followed 235 women who were experiencing gynecologic symptoms and turned to Google for help. Researchers say these women ended up being referred to a specialist after their symptoms were suspected of being possible signs of cancer.
- To help researchers finetune their predictive model, they analyzed women researching their symptoms online with questionnaires given during the study.
- Among the key takeaways is that this study helps develop early detection tools for a cancer that is hard to catch in its early stages.
- Ovarian cancer is often harder to catch in its early stages because of its subtle symptoms, such as bloating, weight gain, and abdominal pain that can mimic regular menstrual cycle fluctuations. After ovarian cancer patients complete initial treatment, maintenance therapy may be recommended to try and delay possible recurrence.
- Maintenance therapy for ovarian cancer can involve taking an oral pill called a PARP inhibitor every day after chemotherapy and can keep cancer in remission longer. PARP inhibitors prevent cancer cells from repairing their DNA.
A new research study published in BMC Public Health involved more than 230 women who researched terms like bloating, pelvic pain, and urinary symptoms. These women ended up being referred to a specialist after their symptoms were suspected of being possible signs of cancer. What’s more, the researchers say they were able to analyze the online search data to determine the differences between people with benign gynecological symptoms and those with potential ovarian or endometrial cancer.
“Ovarian cancer does not have any specific symptoms,” Dr. Beth Karlan, a gynecologic oncologist at UCLA Medical Center, told SurvivorNet.
Many ovarian cancers begin in the fallopian tubes. A few cancerous cells first grow on the fallopian tubes. Then, as the fallopian tubes brush over the ovary, these cells stick to the ovaries and eventually form a tumor.
“The symptoms include things like feeling full earlier than you usually would when your appetite is strong and feeling bloated, some changes in your bowel habits, and some pain in the pelvis. These are symptoms women may have every month. These are not very specific, but we’ve found this constellation of symptoms from multiple studies,” Dr. Karlan added.
The symptoms of ovarian cancer may include the following, according to SurvivorNet experts.
- A feeling of bloating or fullness
- Pain in the pelvis or abdomen
- Nausea
- Vomiting
- Changes in bowel habits
How the Study Was Conducted
The study ran from December 2020 to July 2022. It was conducted by researchers at Imperial College London and University College London and examined 235 women with a median age of 53 Googling habits related to noteworthy symptoms. Most of the women were post-menopausal.
RELATED: Google Denies Access to Medical Sites Offering Critical Health Information
“There was a difference in online search data between those with a benign and malignant diagnosis, noted as early as 360 days in advance of GP referral, when search queries were used directly, but only 60 days in advance, when queries were divided into health categories,” the researchers said.
To help researchers finetune their predictive model, they analyzed women researching their symptoms on Google with questionnaires given during the study.
“The 235 women in the cohort made 519,048 health-related queries (an average of 2208 searches per patient). The rate of malignancy was 26.0% (61/235), with predominantly ovarian (n = 42, 68.9%), followed by endometrial (n = 15, 24.6%) cancer,” the researchers said.
RELATED: Remain Cautious Regarding Cancer Content Promoted on Social Media
Among the key takeaways is that this study helps develop early detection tools for a cancer that is hard to catch in its early stages.
RELATED: ChatGPT Is ‘Not Reliable’ For Cancer Information According to Study
Helping Patients Understand Treatment Options for Ovarian Cancer
More on Ovarian Cancer and Treatment
The standard of care for ovarian cancer patients is chemotherapy, which helps many patients reach remission.
Ovarian cancer recurrence happens in “almost 25 percent of cases with early-stage diseases and in more than 80 percent with more advanced stages,” according to research published in Gland Surgery medical journal. With recurrence a strong possibility for this disease, especially in the later stages of ovarian cancer, certain drug treatments to deal with it are giving many women hope.
WATCH: Treating ovarian cancer.
Ovarian cancer is sub-categorized into two groups.
- Platinum-Sensitive Ovarian Cancer: Your cancer does not return for more than six months after treatment with platinum-based chemotherapies, like carboplatin and cisplatin.
- Platinum-Resistant Ovarian Cancer: Your cancer returns within six months of treatment with platinum-based chemotherapies, like carboplatin and cisplatin.
“The mechanism that causes platinum resistance will cause someone to be resistant to other chemotherapies, as well. That’s why we’re looking for what we call targeted therapies – precision medicine,” Dr. Noelle Cloven from Texas Oncology-Fort Worth Cancer Center explained.
Targeted therapies or precision medicine specifically target the proteins controlling cancer cells’ growth, division, and spread.
Maintenance Therapy for Ovarian Cancer
Maintenance therapy is continued treatment after the patient finishes their initial treatment. After an ovarian cancer patient completes a round of treatments — such as surgery and chemotherapy — her doctor may recommend some form of maintenance therapy to try and delay possible recurrence. Maintenance therapy can involve taking an oral pill called a PARP inhibitor every day after chemotherapy and can keep cancer in remission longer.
Genetic testing helps doctors determine the best maintenance therapy.
“The biggest question is: How do you choose between bevacizumab (brand name, Avastin) or a PARP inhibitor for maintenance therapy?” Dr. Alpa Nick, a gynecological oncologist with Tennessee Oncology in Nashville, tells SurvivorNet.
The drugs combat cancer cells in very different ways. PARP inhibitors prevent cancer cells from repairing their DNA, while Avastin blocks the formation of new blood vessels, starving tumors of nutrients.
The Food and Drug Administration approved bevacizumab (Avastin) to be used in conjunction with olaparib (brand name LYNPARZA) in HRD (Homologous Recombination Deficiency) positive women who show a response to platinum-based chemotherapy. During clinical trials, the drug combination increased progression-free survival from an average of 17 months to 37 months.
“A patient really has to make a decision upfront, or near the beginning of their treatment, that they want bevacizumab maintenance treatment because they’ll have it with their primary chemotherapy,” Dr. Nick explains.
The drug is administered intravenously and can be given in combination with other chemotherapy drugs. Avastin affects the growth of blood vessels, starving tumors of the blood they need as nourishment.
The American Society of Clinical Oncology (ASCO) guidelines recommend PARP inhibitors be offered to women, with or without genetic mutations, who are newly diagnosed with stage III or IV ovarian cancer and have improved with chemotherapy.
Surgery offers another critical decision point. “When patients have their surgery, we can test their tumor to decide if their tumor has a homologous recombination deficiency,” known as HRD. If it does, that also suggests they would benefit from PARP inhibitor maintenance therapy,” says Dr. Nick.
Elahere (molecular name mirvetuximab) is an FDA-approved targeted therapy that provides much-needed hope for patients with platinum-resistant ovarian cancer. This drug treatment is for women who test positive for a molecular factor called folate receptor alpha (FRα). While many ovarian cancers test positive for the folate receptor, to be eligible for Elahere, you must have very high levels (>75%) of the folate receptor-alpha (FRα).
It is an antibody-drug conjugate. This kind of new anti-cancer drugs, known as “biological missiles,” is leading a new era of targeted cancer therapy.
Dr Lyons explains, “What that means is that the antibody part of the drug conjugates binds to the folate receptor on the tumor cells, and then that gets taken up into the tumor cell. And then the drug that is conjugated with is the part that kills the tumor cells by affecting the tumor cell’s ability to divide.”
Questions for Your Doctor
If you have been diagnosed with ovarian cancer and need guidance to further educate yourself on the disease and treatment, consider these questions for your doctor.
- What type of ovarian cancer do I have?
- What stage is my cancer in?
- Do you recommend I get genetic testing for any gene mutations, such as the BRCA gene mutation?
- What initial treatment options do you recommend?
- What are the possible side effects of the recommended treatment, and how can they be coped with?
- Will insurance help cover my recommended treatment?
Learn more about SurvivorNet's rigorous medical review process.